{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-258006","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.891995+00:00","generated_at":"2026-05-30T00:35:25.179817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M","bullets":["Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.","Organizational restructuring: closing Rockville research site, reducing workforce ~46%, focusing on SNS-101.","SNS-101 Phase 1/2 dose expansion clinical data expected in H1 2025; enrollment ~50% complete.","Appointed Josiah Craver as SVP Finance, principal financial and accounting officer in September."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-258006","json":"https://secwatch.observer/filing/0001193125-24-258006.json","markdown":"https://secwatch.observer/filing/0001193125-24-258006.md","text":"https://secwatch.observer/filing/0001193125-24-258006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/0001193125-24-258006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/d855965d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:35:25.179817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}